Vertex Pharmaceuticals Incorporated earnings overview

VRTX FY2026 Q1 · Calendar Q2 2026

Vertex Pharmaceuticals Incorporated

Vertex is executing a deliberate shift from a single-franchise CF company to a multi-pillar biotech. Q1 2026 revenue of $2.99 billion (up 8% YoY) was driven by both the core CF franchise and new non-CF launches KASJEVY and GERNAVICS, which together contributed roughly a quarter of growth. The interim Phase III IgAN data for Povi — 52% proteinuria reduction with a strong safety profile — and the record 27-day BLA submission position the renal franchise as Vertex's emerging fourth commercial pillar. Label expansions for AlifTrack and TRIKAFTA now cover approximately 95% of the CF population, extending the durability of the core franchise. Management reaffirmed full-year guidance of $12.95–$13.10 billion, signaling confidence in the trajectory despite the VX-522 mRNA CF program discontinuation. The stock traded with a -2.1% abnormal return in the reaction window on 1.8x baseline volume…